BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31475201)

  • 1. Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy.
    Liu S; Ren SN; Ding WX; Ge XL; Cao YD; Zhang S; Zhen FX; Sun XC
    Ann Transl Med; 2019 Jul; 7(14):331. PubMed ID: 31475201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
    Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
    Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
    Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
    Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
    Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
    Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.
    Yi Q; Liu C; Cui Y; Yang Y; Li Y; Fan X; Wu K
    Cancer Med; 2023 Mar; 12(6):6477-6487. PubMed ID: 37012831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study.
    Zhang W; Xie Q; Zhu B; Wang X; He L; Zhang Y
    Medicine (Baltimore); 2022 Apr; 101(16):e29166. PubMed ID: 35482986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
    Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
    JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
    Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
    Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial.
    Wang D; Zhang W; Qian D; Guan Y; Chen X; Zhang H; Wang J; Pang Q
    Onco Targets Ther; 2018; 11():6333-6338. PubMed ID: 30319273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J; Yin W; Yao H; Gu W
    Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy.
    Chen C; Chen T; Huang C; Wang J; Fei Z
    Medicine (Baltimore); 2017 Nov; 96(44):e8434. PubMed ID: 29095283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the prognostic factors of simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT) in 220 cases of locally advanced squamous esophageal cancer: a retrospective cohort study.
    Zhou S; Yang Y; Zhang Q; Zhu C; Cai P; Li D
    Ann Transl Med; 2023 Jan; 11(2):103. PubMed ID: 36819557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed and cisplatin for locally advanced oesophageal squamous cell carcinoma.
    Fu C; Li B; Guo L; Li H; Huang W; Gong H; Sun M; Wang Z; Zhou T; Liu C
    Br J Radiol; 2014 May; 87(1037):20130656. PubMed ID: 24666012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.